IMRN Stock Price and Chart — NASDAQ:IMRN — TradingView

Compare with Immuron Limited

Key stats

Upcoming earnings

Details

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

$IMRN Immuron stock rockets after funding by U.S. DoD of new research agreement Shares of Immuron Ltd. IMRN, +46.18% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Departme

by BADQOMOCAWGOWLD

About to breakout !!The Company www.immuron.com.au Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we be

by UnknownUnicorn10209036

ASX:IMC IMC - Break of LT DT - finding base watching

IMC Covid-19 Simple Solution ?themarketherald.com.au Immuron's (IMC) share price has more than doubled on the news a drug used in its traveller's diarrhoea formulation neutralises activity aginst the COVID-19 virus The company tested its IMM-124E treatment and has seen antiviral activity against SARS-CoV-2, the virus th

by RAZORSWINGTRADER

Immuron’s products found to neutralise Covid-19 Immuron’s commercially available products found to neutralise COVID-19 during in vitro research smallcaps.com.au Immuron’s commercially available products found to neutralise COVID-19 during in vitro research By Lorna Nicholas - July 21, 2020 Immuron ASX IMC NASDAQ IMRN SARS-CoV-2 COVID-19 antivi

by RAZORSWINGTRADER

NMRC received guidance from the FDA NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC -Two human phase II clinical trials to be conducted in 2021 -One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobact

IMRN Looks like a big wave is coming, announced new partnership what do you guys think?

NMRC Requests Meeting with FDA for Guidance on two Phase 2 trial US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials

IMC long position Up trending everywhere i dont know if this will work out. But i'm trying to learn.

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

An aggregate view of professional's ratings.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.